Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$289.33 -0.1%	$281.82	$253.30 ▼ $346.85	$155.57B	0.51	2.82 million shs	6.80 million shs
BIIB Biogen	$127.04 +0.4%	$124.83	$110.04 ▼ $238.00	$18.61B	0.14	1.43 million shs	2.17 million shs
GILD Gilead Sciences	$108.50 +0.5%	$106.16	$66.01 ▼ $119.96	$134.97B	0.29	7.66 million shs	23.27 million shs
MRNA Moderna	$25.90 +2.0%	$26.28	$23.15 ▼ $138.07	$10.02B	1.86	8.50 million shs	13.76 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	0.00%	-2.00%	+6.41%	-8.45%	-5.44%
BIIB Biogen	0.00%	-2.76%	+0.59%	-9.84%	-43.20%
GILD Gilead Sciences	0.00%	-1.35%	+1.65%	+1.33%	+71.81%
MRNA Moderna	0.00%	-2.89%	-3.07%	-20.70%	-80.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.408 of 5 stars	2.2	4.0	3.3	3.9	3.1	2.5	0.6
BIIB Biogen	4.7958 of 5 stars	4.2	3.0	0.0	3.7	2.6	1.7	2.5
GILD Gilead Sciences	4.9672 of 5 stars	2.4	5.0	4.2	4.1	3.4	2.5	3.1
MRNA Moderna	4.4604 of 5 stars	4.0	2.0	0.0	4.6	1.5	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.38	Hold	$309.22	6.87% Upside
BIIB Biogen	2.38	Hold	$188.19	48.13% Upside
GILD Gilead Sciences	2.78	Moderate Buy	$110.55	1.89% Upside
MRNA Moderna	2.04	Hold	$46.61	79.97% Upside

Current Analyst Ratings Breakdown

Latest GILD, AMGN, BIIB, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/2/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/22/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$33.00 ➝ $26.00
5/21/2025	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/20/2025	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$288.00
5/16/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$329.00 ➝ $328.00
5/8/2025	AMGN Amgen	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	AMGN Amgen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$235.00 ➝ $280.00
5/7/2025	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$207.00 ➝ $169.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.65	$30.36 per share	9.53	$10.93 per share	26.47
BIIB Biogen	$9.68B	1.92	$23.10 per share	5.50	$114.71 per share	1.11
GILD Gilead Sciences	$28.75B	4.69	$6.87 per share	15.79	$15.44 per share	7.03
MRNA Moderna	$3.24B	3.10	N/A	N/A	$28.33 per share	0.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	26.40	13.53	2.62	17.39%	176.11%	12.39%	8/5/2025 (Estimated)
BIIB Biogen	$1.63B	$10.13	12.54	7.69	1.00	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	22.84	13.38	0.70	20.76%	51.93%	17.40%	8/6/2025 (Estimated)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	7/30/2025 (Estimated)

Latest GILD, AMGN, BIIB, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.29%	N/A	86.86%	14 Years
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.91%	N/A	66.53%	10 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Latest GILD, AMGN, BIIB, and MRNA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	8.70	1.17	0.88
BIIB Biogen	0.27	1.44	1.01
GILD Gilead Sciences	1.16	1.37	1.23
MRNA Moderna	N/A	4.22	4.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BIIB Biogen	87.93%
GILD Gilead Sciences	83.67%
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.76%
BIIB Biogen	0.18%
GILD Gilead Sciences	0.27%
MRNA Moderna	11.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.71 million	533.62 million	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable

GILD, AMGN, BIIB, and MRNA Headlines

Recent News About These Companies

Everything to know about the Moderna COVID-19 vaccine

June 21 at 4:14 AM | medicalnewstoday.com

Moderna (MRNA) Advances While Market Declines: Some Information for Investors

June 20 at 6:51 PM | zacks.com

Rakuten Securities Inc. Boosts Stock Position in Moderna, Inc. (NASDAQ:MRNA)

June 17, 2025 | marketbeat.com

Moderna, Inc. (MRNA) Presents at Barclays Speaking the Science Call Series Transcript

June 16, 2025 | seekingalpha.com

Moderna (NASDAQ:MRNA) Stock Price Down 3.8% - Here's What Happened

June 16, 2025 | marketbeat.com

False claim flips facts on mRNA vaccine nerve disease risk

June 16, 2025 | aap.com.au

Barclays Speaking the Science Call Series

June 16, 2025 | seekingalpha.com

27,611 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by BDF Gestion

June 16, 2025 | marketbeat.com

Moderna, Inc. (NASDAQ:MRNA) Shares Sold by SG Americas Securities LLC

June 16, 2025 | marketbeat.com

Celebrated, then disparaged: mRNA’s promise is tarnished under Trump

June 14, 2025 | msn.com

Investors Purchase High Volume of Moderna Call Options (NASDAQ:MRNA)

June 14, 2025 | marketbeat.com

Fact check: HHS misleads on mRNA vaccine safety after pulling Moderna funding

June 13, 2025 | nbcwashington.com

Here's Why Moderna (MRNA) Fell More Than Broader Market

June 13, 2025 | zacks.com

FDA Approves Expanded Indication for Moderna’s Respiratory Syncytial Virus Vaccine mRESVIA

June 13, 2025 | pharmexec.com

FDA expands approval of Moderna's RSV vaccine to some adults under age 60

June 13, 2025 | msn.com

FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains

June 13, 2025 | msn.com

Moderna falls on doubts over new CDC panel's backing of RSV vaccine

June 13, 2025 | msn.com

HHS Misleads on mRNA Vaccine Safety After Pulling Moderna Funding

June 13, 2025 | msn.com

Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects

June 13, 2025 | reuters.com

Moderna’s RSV Vaccine Gets FDA Nod For Younger At-Risk Adults: Retail Stays Guarded Amid RFK Jr’s Immunization Shake-Up

June 13, 2025 | msn.com

FDA expands Moderna's RSV vaccine approval to at-risk adults

June 13, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD, AMGN, BIIB, and MRNA Company Descriptions

Amgen NASDAQ:AMGN

$289.33 -0.30 (-0.10%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$289.95 +0.62 (+0.21%)

As of 06/20/2025 07:58 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen NASDAQ:BIIB

$127.04 +0.50 (+0.40%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$127.24 +0.20 (+0.16%)

As of 06/20/2025 06:59 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gilead Sciences NASDAQ:GILD

$108.50 +0.50 (+0.46%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$108.85 +0.35 (+0.32%)

As of 06/20/2025 07:58 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Moderna NASDAQ:MRNA

$25.90 +0.50 (+1.97%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$25.93 +0.03 (+0.12%)

As of 06/20/2025 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time